New injection aims to tame chronic hepatitis b

NCT ID NCT06115993

Completed Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive either AHB-137 or a placebo injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-137 injection
What this could lead to: If successful, this could point toward a new treatment option that helps control chronic hepatitis B more effectively.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. Side effects and lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B CHRONIC

Contacts and locations

Locations

Nanfang Hospital, Southern Medical University

Guangzhou, China
The First Hospital of Jilin University

Jilin City, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.